(UroToday.com) At the metastatic castration resistant prostate cancer (mCRPC) session at the Society of Nuclear Medicine & Molecular Imaging 2021 Annual Meeting, Dr. Daniel Lee discussed osseous molecular radiotherapy for mCRPC. Dr. Lee highlighted that mCRPC is the terminal phase of the disease, with a poor prognosis, encompassing many patients with primarily skeletal disease. Indeed, skeletal disease is the major determinant of morbidity and mortality, affecting both hematopoiesis and structural integrity. Radiotherapy in prostate cancer includes Sr-89 (Metastron®), Sm-153 EDTMP (Quadramet®), and radium-223 (Xofigo®).